The SLC2A2 gene gives your body instructions for GLUT2, a protein that moves sugar in and out of certain cells, especially in the liver, pancreas, kidneys, and intestine. This gene helps your body sense blood sugar levels and handle glucose after you eat or between meals. If it does not work properly, sugar control can be disrupted, and some people develop Fanconi-Bickel syndrome, which can cause poor growth, liver enlargement, kidney problems, and soft bones.
What is a gene?
Genes are stretches of DNA that hold instructions your cells use to make molecules or to manage processes throughout the body. Some genes carry the code for producing proteins, which are the parts of cells that do much of the work. Others are used mainly to regulate when certain processes happen, where they take place, and how active they are. Taken together, genes affect how the body grows and works, and they can also influence how you react to food, stress, or medicines. For a deeper look at this topic, visit the LearnHub.
Overview
SLC2A2Gene function
What if the gene works
The SLC2A2 gene helps certain cells move sugar, especially glucose, into and out of the cell. This supports blood sugar sensing and sugar handling in the liver, pancreas, kidneys, and intestines.
Risk
What if the gene does not work
More severe SLC2A2 gene variants can cause Fanconi-Bickel syndrome, with enlarged liver, kidney tubule problems, poor growth, and blood sugar swings. Milder variants may preserve some transport activity, which can affect how early features appear and how marked they are.
Treatment
What does that mean for your treatment
Pathogenic variants in the SLC2A2 gene do not currently have a targeted drug treatment. Management is tailored to the metabolic and kidney effects, often using frequent feeds or uncooked cornstarch, limiting galactose, and replacing bicarbonate, phosphate, potassium, and vitamin D when needed. These measures help steady blood sugar and support bone and kidney health.
Conditions associated with SLC2A2
Gene function
What if the gene works
Some cells need a fast way to move sugar across their surface, especially after you eat or between meals. In simple terms, SLC2A2 gene function centers on moving glucose where it is needed and helping the body keep blood sugar in balance. Its protein, often called GLUT2, is active in the liver, intestine, kidneys, and some pancreas cells.
The SLC2A2 gene makes a transporter that moves glucose across the cell surface. It can move sugar in either direction, depending on the needs of the cell and the bloodstream.
In liver cells, this transporter helps glucose move in after meals and move out between meals. This supports normal energy storage and steady sugar release.
In the small intestine, it helps absorbed sugars leave gut lining cells and enter the bloodstream. This allows energy from food to become available to the rest of the body.
In the kidneys, it helps filtered glucose move from kidney cells back into the blood. This supports normal sugar conservation while urine is being formed.
What is a variant?
A genetic variant is a minor alteration in the DNA sequence of a gene. These changes are common and help shape normal human diversity, including differences in appearance, metabolism, or how the body responds to environmental influences. Many variants do not have any noticeable effect and simply represent natural genetic variation. In some situations, however, a variant can change how a gene functions more substantially and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the SLC2A2 gene can alter the GLUT2 sugar transporter so it is made in smaller amounts, folds poorly, or does not reach the cell surface, which means glucose moves less effectively across the cell membrane. SLC2A2 gene variant effects range from milder changes that partly reduce transport to more severe variants that nearly eliminate it. In Fanconi-Bickel syndrome, more disruptive variants often lead to earlier and broader symptoms.
How variants are linked to conditions
Pathogenic variants in the SLC2A2 gene cause Fanconi-Bickel syndrome, a rare inherited condition linked to poor growth, low blood sugar, liver enlargement, and kidney problems. In contrast, some common SLC2A2 gene variants have been associated in population studies with differences in blood sugar levels and type 2 diabetes risk, but these links do not mean a person will develop diabetes.
A variant is not necessarily a diagnosis
Genetic variants are a routine part of human biology and are widely seen in the general population. Most do not have a direct effect on health and simply reflect natural human diversity. For many genes, carrying a variant associated with a condition suggests a possible link rather than a definite diagnosis, especially when several genes and environmental factors are involved. In some cases, though, a single well-characterized variant in a specific gene can by itself confirm a diagnosis.
Are there things that can increase or change my risk?
For SLC2A2, risk is mainly shaped by inheritance rather than lifestyle. A child’s chance of having the related condition is much higher when both parents carry a disease-causing change in the SLC2A2 gene, and this can be more likely in families with shared ancestry. There is not enough evidence to say that diet, exercise, or other daily habits lower this genetic risk.
Inheritance of SLC2A2 variants
SLC2A2-related Fanconi-Bickel syndrome follows an autosomal recessive inheritance pattern. This means a child inherits one SLC2A2 gene variant from each parent, and the parents are usually healthy carriers. When both parents carry a variant in the SLC2A2 gene, each pregnancy has a 25% chance of being affected, a 50% chance that the child will be a carrier, and a 25% chance of inheriting neither variant. Sons and daughters are affected equally because the SLC2A2 gene is on chromosome 3, not a sex chromosome.
What does my SLC2A2 result mean for my family?
For families with a disease-causing change in the SLC2A2 gene, the usual pattern is recessive, which means parents are often healthy carriers. Brothers and sisters may also have the condition or be carriers, and other close relatives may be carriers too. Because of that, relatives may want to talk with their care team about whether family testing would be useful.
Genetic information
Genetic testing
How you find out about variants
SLC2A2 genetic testing looks for variants in the SLC2A2 gene using a blood sample, saliva, or a cheek swab. A lab reads the gene’s DNA code, often as part of a broader panel, and the results can show whether you carry a variant linked to a confirmed genetic diagnosis or a carrier state.
When should I consider getting a genetic test?
Consider testing the SLC2A2 gene if a baby or child has signs of Fanconi-Bickel syndrome, such as poor growth, an enlarged liver, weak or bowed bones, and sugar leaking into the urine. Testing may also make sense when this condition runs in the family or when both parents are known carriers.
A genetic result is only one part of your health story
A genetic result can provide useful insight, but how much it can tell you varies by the condition and the kind of variant involved. Over time, many factors, including lifestyle, environment, age, and medical history, also influence how the body works. For some conditions, especially those shaped by many genes, genetic information provides context rather than certainty and is best considered together with other parts of care. In other situations, a genetic result may offer a clear answer. In areas like medication response, genetic results can also help put individual experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. Small differences in genes can change how the body absorbs, breaks down, moves, or responds to a drug. This helps explain why the same treatment works well for one person, works less well for another, or causes more side effects in someone else. These differences are common and are only one part of the picture, alongside age, overall health, and other medicines.
What is Pharmacogenetics?
Pharmacogenetics examines how differences in genes affect the way people respond to medications. It looks at gene drug patterns to help explain why the same treatment may work differently from one person to another. For many medicines, genes influence both how strongly a drug works and how the body processes it. This information can support treatment choices that are more informed and more individualized. You can explore this topic further in the LearnHub.
Drugs influenced by the SLC2A2 gene
When should I seek medical advice?
There isn't yet a broadly confirmed role for this gene in guiding how medicines are chosen or adjusted, so any concerns about treatment, side effects, or blood sugar are best discussed with your doctor. SLC2A2 has been studied for a possible link to how some people respond to metformin, but this research is not used as routine guidance for care.
History
The SLC2A2 gene entered medical research in the late 1980s, when scientists were identifying the family of genes that make glucose transport proteins. Soon after, researchers mapped it to chromosome 3 and connected it to sugar handling in the liver, pancreas, kidney, and intestine. Building on this early work, scientists uncovered more about the gene when rare inherited variants were found to cause Fanconi-Bickel syndrome, a condition affecting blood sugar balance and glycogen storage. Later studies linked common SLC2A2 variants to differences in blood sugar levels and type 2 diabetes risk. Although it has stayed mostly outside the public spotlight, the gene has remained important in research on metabolism and diabetes.